S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:SGMO

Sangamo Therapeutics (SGMO) Stock Price, News & Analysis

$0.62
+0.02 (+3.31%)
(As of 03/27/2024 ET)
Today's Range
$0.59
$0.64
50-Day Range
$0.42
$1.38
52-Week Range
$0.29
$1.82
Volume
2.65 million shs
Average Volume
2.29 million shs
Market Capitalization
$111.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.93

Sangamo Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
688.4% Upside
$4.93 Price Target
Short Interest
Bearish
6.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of Sangamo Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.54) to ($0.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.15 out of 5 stars

Medical Sector

792nd out of 939 stocks

Biological Products, Except Diagnostic Industry

130th out of 151 stocks

SGMO stock logo

About Sangamo Therapeutics Stock (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

SGMO Stock Price History

SGMO Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Sangamo Therapeutics Inc
SGMO Apr 2024 1.500 put
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
SGMO Apr 2024 1.500 call
SGMO Apr 2024 3.000 call
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
Sangamo Therapeutics, Inc. (SGMO)
Sangamo Therapeutics (SGMO) Earnings Dates & Reports
See More Headlines
Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2023
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:SGMO
CUSIP
80067710
Employees
478
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$4.93
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+688.4%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-257,830,000.00
Net Margins
-146.30%
Pretax Margin
-149.18%

Debt

Sales & Book Value

Annual Sales
$176.23 million
Cash Flow
$0.04 per share
Book Value
$0.47 per share

Miscellaneous

Free Float
173,539,000
Market Cap
$111.77 million
Optionable
Optionable
Beta
1.44

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Alexander D. Macrae Ch.B (Age 61)
    M.B., MRCP, Ph.D., CEO, President & Director
    Comp: $1.17M
  • Ms. Amy Pooler Ph.D.
    Head of Research
  • Mr. Gregory Davis Ph.D.
    Head of Technology
  • Ms. Aron Feingold
    Head of Corporate Communications & Investor Relations Officer
  • Mr. Scott B. Willoughby (Age 49)
    Senior VP, General Counsel & Corporate Secretary
  • Dr. Nathalie Dubois-Stringfellow Ph.D. (Age 62)
    Senior VP & Chief Development Officer
  • Dr. Lisa Rojkjaer M.D. (Age 58)
    Chief Medical Officer
  • Phillip Ramsey
    Head of Technical Operations
  • Ms. Stephanie J. Seiler CLP
    Head of Business Development & Alliance Management
  • Mr. David Ojala
    Scientist II - Discovery & Translational Research

SGMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGMO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGMO, but not buy additional shares or sell existing shares.
View SGMO analyst ratings
or view top-rated stocks.

What is Sangamo Therapeutics' stock price target for 2024?

7 analysts have issued twelve-month price targets for Sangamo Therapeutics' shares. Their SGMO share price targets range from $1.00 to $10.00. On average, they expect the company's stock price to reach $4.93 in the next year. This suggests a possible upside of 688.4% from the stock's current price.
View analysts price targets for SGMO
or view top-rated stocks among Wall Street analysts.

How have SGMO shares performed in 2024?

Sangamo Therapeutics' stock was trading at $0.5433 at the start of the year. Since then, SGMO stock has increased by 15.0% and is now trading at $0.6247.
View the best growth stocks for 2024 here
.

When is Sangamo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our SGMO earnings forecast
.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced its earnings results on Wednesday, February, 22nd. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. The biopharmaceutical company earned $27.23 million during the quarter, compared to analysts' expectations of $26.86 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 82.17% and a negative net margin of 146.30%. The business's quarterly revenue was down 2.7% on a year-over-year basis. During the same period last year, the company posted ($0.26) EPS.

What ETFs hold Sangamo Therapeutics' stock?

ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR).Global X Genomics & Biotechnology ETF (GNOM).

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.10%), Vanguard Group Inc. (7.10%), Wasatch Advisors LP (6.99%), Northern Trust Corp (0.71%), GSA Capital Partners LLP (0.61%) and Assenagon Asset Management S.A. (0.58%). Insiders that own company stock include Biogen Inc and John Markels.
View institutional ownership trends
.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SGMO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners